- Joined
- Jun 26, 2001
- Messages
- 723
- Reaction score
- 294
Now I love EBM - I am a very strong advocate - but I think one of its weakest points involve when to stop treatment and testing.
There is very little to no evidence outside of PSA of when to stop screening.
Should you really screen a 89 year old for hyperlipidemia? Would it really extend her life? Or do the side effects of the medications negate any marginal benefit she would get?
Should permissive HTN (which is slightly touched on with the new guidelines) be allowed in the elderly? is the risks of falls and increased mortality from falls outweigh the benefits of controlling HTN strictly?
Would about hga1c? Stricter control leads to more hypoglycemic episodes in the elderly, who are also at risk for lacking the symptoms of hypoglycemia.
There is very little to no evidence outside of PSA of when to stop screening.
Should you really screen a 89 year old for hyperlipidemia? Would it really extend her life? Or do the side effects of the medications negate any marginal benefit she would get?
Should permissive HTN (which is slightly touched on with the new guidelines) be allowed in the elderly? is the risks of falls and increased mortality from falls outweigh the benefits of controlling HTN strictly?
Would about hga1c? Stricter control leads to more hypoglycemic episodes in the elderly, who are also at risk for lacking the symptoms of hypoglycemia.